Under physiological conditions, the vascular endothelium is in a quiescent state characterized by a limited interaction with circulating leukocytes. Upon injury, the endothelial cells shift to an activated phenotype, involving increased adhesion molecules expression, such as P-Selectin, E-selectin, VCAM-1, ICAM-1, and MAdCAM-1, on their luminal surface. These proteins are involved in the initial recruitment of leukocytes and in their firm adhesion to the endothelial wall. By conjugating imaging contrast agents to specific antibodies, we can essentially “see” the expression of these adhesion molecules and reveal inflammatory processes. We synthesize biodegradable microsized ferromagnetic particles that enable the imaging of these processes with high sensitivity (Gauberti et al., 2018, Theranostics).  We have named this approach “immuno-imaging“, to describe this powerful technology and its wide range of applications across different imaging modalities, which include early diagnosis, detecting subclinical injury, monitoring therapeutic response, and grading the severity of inflammatory disorder.